MCID: MLG064
MIFTS: 45

Malignant Ependymoma

Categories: Cancer diseases, Genetic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Malignant Ependymoma

MalaCards integrated aliases for Malignant Ependymoma:

Name: Malignant Ependymoma 12 15
Ependymal Neoplasm 12 17
Ependymal Tumors 12 56
Experimental Organism Malignant Ependymoma 74
Anaplastic Ependymoma 74
Ependymoma of Brain 74
Ependymal Tumor 74

Classifications:



External Ids:

Disease Ontology 12 DOID:5074
NCIt 51 C6770

Summaries for Malignant Ependymoma

Disease Ontology : 12 A malignant glioma that is derived from ependymal cells, a type of glial cell, located in ventricle lining within the central part of the brain.

MalaCards based summary : Malignant Ependymoma, also known as ependymal neoplasm, is related to benign ependymoma and spinal cord ependymoma, and has symptoms including seizures, vomiting and headache. An important gene associated with Malignant Ependymoma is NF2 (Neurofibromin 2), and among its related pathways/superpathways is Hippo signaling pathway - multiple species. The drugs Carboplatin and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and bone marrow, and related phenotypes are immune system and digestive/alimentary

Related Diseases for Malignant Ependymoma

Graphical network of the top 20 diseases related to Malignant Ependymoma:



Diseases related to Malignant Ependymoma

Symptoms & Phenotypes for Malignant Ependymoma

UMLS symptoms related to Malignant Ependymoma:


seizures, vomiting, headache, nausea

MGI Mouse Phenotypes related to Malignant Ependymoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.87 CD207 EPB41 ERCC5 GFAP NF2 RELA
2 digestive/alimentary MP:0005381 9.77 ERCC5 GFAP LOXL3 RELA YAP1
3 integument MP:0010771 9.65 ERCC5 LOXL3 NF2 RELA YAP1
4 liver/biliary system MP:0005370 9.63 CD207 EPB41 ERCC5 NF2 RELA YAP1
5 respiratory system MP:0005388 9.35 CD207 LOXL3 NF2 RELA YAP1
6 vision/eye MP:0005391 9.02 ARVCF GFAP LOXL3 NF2 RELA

Drugs & Therapeutics for Malignant Ependymoma

Drugs for Malignant Ependymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 216)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 38904 10339178 498142
2
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 6055-19-2, 50-18-0 2907
3
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
4
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
6
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
7
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 441203 84093 2767
8
Dopamine Approved Phase 3,Early Phase 1,Not Applicable 62-31-7, 51-61-6 681
9
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
10 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
11
Emodepside Investigational, Vet_approved Phase 3 155030-63-0
12 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
13 Etoposide phosphate Phase 3,Phase 2
14 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
15 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
16 Keratolytic Agents Phase 3,Phase 1,Phase 2
17 Antimitotic Agents Phase 3,Phase 1,Phase 2
18 Alkylating Agents Phase 3,Phase 2,Phase 1
19 Immunologic Factors Phase 3,Phase 2,Phase 1
20 Topoisomerase Inhibitors Phase 3,Phase 2
21 Podophyllotoxin Phase 3,Phase 1,Phase 2 518-28-5
22 Antirheumatic Agents Phase 3,Phase 2
23 Dermatologic Agents Phase 3,Phase 1,Phase 2
24 Antineoplastic Agents, Phytogenic Phase 3,Phase 1,Phase 2
25 Cola Phase 3,Phase 1
26 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
27 Analgesics, Opioid Phase 3
28 Anesthetics Phase 3
29 Anesthetics, Intravenous Phase 3
30 Narcotics Phase 3
31 Adjuvants, Anesthesia Phase 3
32 Analgesics Phase 3,Phase 2,Phase 1
33 Liver Extracts Phase 3,Phase 2,Phase 1
34 Anesthetics, General Phase 3
35 Cholinesterase Inhibitors Phase 3,Phase 2
36 Nootropic Agents Phase 3,Phase 2
37 Neurotransmitter Agents Phase 3,Phase 2,Early Phase 1,Not Applicable
38 Cholinergic Agents Phase 3,Phase 2
39 Central Nervous System Stimulants Phase 3,Phase 2
40 Dopamine Agents Phase 3,Early Phase 1,Not Applicable
41 Dopamine Uptake Inhibitors Phase 3
42 Dexmethylphenidate Hydrochloride Phase 3
43 Neurotransmitter Uptake Inhibitors Phase 3
44
Sargramostim Approved, Investigational Phase 2,Phase 1 123774-72-1, 83869-56-1
45
Lenograstim Approved, Investigational Phase 2,Phase 1 135968-09-1
46
Mesna Approved, Investigational Phase 2 3375-50-6 598
47
Carmustine Approved, Investigational Phase 1, Phase 2,Phase 2 154-93-8 2578
48
Ethanol Approved Phase 1, Phase 2 64-17-5 702
49
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
50
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177 70789204

Interventional clinical trials:

(show top 50) (show all 91)
# Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
3 Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma Recruiting NCT01096368 Phase 3 Carboplatin;Cisplatin;Cyclophosphamide;Etoposide;Vincristine Sulfate Liposome
4 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
5 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
6 Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma Unknown status NCT00027846 Phase 2 carboplatin;cyclophosphamide;etoposide;vincristine sulfate;Mesna
7 Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
8 Everolimus for Children With Recurrent or Progressive Ependymoma Completed NCT02155920 Phase 2 Everolimus
9 Etoposide Plus Cisplatin in Treating Patients With Recurrent Ependymomas Completed NCT00002876 Phase 2 cisplatin;etoposide
10 Combination Chemotherapy Plus Radiation Therapy in Treating Adult Patients With Brain Cancer Completed NCT00003309 Phase 2 cisplatin;cyclophosphamide;etoposide;vincristine sulfate
11 Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma Completed NCT00058123 Phase 2 poly ICLC
12 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
13 Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma Completed NCT00826241 Phase 2 Temozolomide;Lapatinib
14 Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma Completed NCT01026493 Phase 1, Phase 2 temozolomide 60 mg x 21 days;temozolomide 75 mg x 21 days;ABT-888 20 mg x 21 days;ABT-888 40 mg x 21 days;Temozolomide 150 mg x 5 days;ABT-888 40 mg x 5 days
15 Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors Completed NCT01032200 Phase 2 Armodafinil
16 Levetiracetam or Pregabalin in Treating Seizures in Patients Undergoing Chemotherapy and/or Radiation Therapy For Primary Brain Tumors Completed NCT00629889 Phase 2 levetiracetam;pregabalin
17 Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors Completed NCT00541138 Phase 2 carboplatin;tamoxifen citrate;topotecan hydrochloride
18 Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma Completed NCT00498927 Phase 2 temozolomide
19 Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma Completed NCT00352521 Phase 2 bevacizumab;irinotecan
20 Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas Completed NCT00274755 Phase 2 chemotherapy
21 Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
22 Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
23 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary Brain Tumors Completed NCT00003478 Phase 1, Phase 2
24 Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor Completed NCT00070161 Phase 2 donepezil hydrochloride
25 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers Completed NCT00002752 Phase 1, Phase 2
26 Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
27 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
28 Carboplatin and Bevacizumab for Recurrent Ependymoma Recruiting NCT01295944 Phase 2 Carboplatin;Bevacizumab
29 Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Recruiting NCT03698994 Phase 2 Ulixertinib
30 Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas Active, not recruiting NCT01478321 Phase 2 Temozolomide
31 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
32 Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma Not yet recruiting NCT03727841 Phase 2 Marizomib
33 Antineoplaston Therapy in Treating Patients With Ependymoma Terminated NCT00003479 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
34 Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma Terminated NCT01095094 Phase 2 ritonavir;lopinavir
35 Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors Terminated NCT01836549 Phase 2 imetelstat sodium
36 Photodynamic Therapy in the Treatment of Malignant Intracranial Tumors Withdrawn NCT00243490 Phase 2
37 Functional Magnetic Resonance Imaging and 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Treating Patients With Newly Diagnosed Brain Tumors Withdrawn NCT00005083 Phase 2
38 Enzastaurin and Temozolomide in Treating Patients With Primary Gliomas Unknown status NCT00516607 Phase 1 enzastaurin hydrochloride;temozolomide
39 Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas Unknown status NCT00083096 Phase 1 lonafarnib;temozolomide
40 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status NCT00002647 Phase 1 verteporfin
41 Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 Completed NCT01082926 Phase 1
42 Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases Completed NCT01234740 Phase 1 bafetinib
43 Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors Completed NCT01131234 Phase 1 Gamma-Secretase Inhibitor RO4929097;Cediranib Maleate
44 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
45 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
46 Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma Completed NCT01480050 Phase 1 temozolomide;Mibefradil
47 Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma Completed NCT00730613 Phase 1
48 A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors Completed NCT00784914 Phase 1 temsirolimus
49 Carmustine in Treating Patients With Recurrent Malignant Glioma Completed NCT00004028 Phase 1 carmustine
50 Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment Completed NCT00544284 Phase 1 bortezomib;temozolomide

Search NIH Clinical Center for Malignant Ependymoma

Genetic Tests for Malignant Ependymoma

Anatomical Context for Malignant Ependymoma

MalaCards organs/tissues related to Malignant Ependymoma:

42
Brain, Bone, Bone Marrow, Liver, Spinal Cord, Kidney, T Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Malignant Ependymoma:

20
Ventricle Lining

Publications for Malignant Ependymoma

Articles related to Malignant Ependymoma:

(show all 16)
# Title Authors Year
1
Response to temozolomide in supratentorial multifocal recurrence of malignant ependymoma. ( 21498732 )
2011
2
Cytologic findings in malignant ependymoma: a case report. ( 21053591 )
2010
3
Cachexia secondary to intracranial anaplastic (malignant) ependymoma in a boxer dog. ( 19796316 )
2009
4
A primary malignant ependymoma of the abdominal cavity: a case report and review of the literature. ( 19238432 )
2009
5
Sacrococcygeal immature teratoma with malignant ependymoma component. ( 19492320 )
2009
6
Supratentorial malignant ependymoma in childhood: 16 years without relapse after hemispherectomy. ( 15095106 )
2005
7
Primary malignant ependymoma of the lung. ( 1548954 )
1992
8
Extracranial metastases of malignant ependymoma--case report. ( 1699151 )
1990
9
Abnormal cilia in a malignant ependymoma. ( 3776464 )
1986
10
Acute leukaemia following malignant ependymoma: a case report. ( 3857395 )
1985
11
Subarachnoid haemorrhage due to widely metastatising malignant ependymoma. ( 4080060 )
1985
12
Malignant ependymoma involving the temporal bone with remote metastasis. ( 4429899 )
1974
13
Malignant ependymoma in a cat. ( 4731360 )
1973
14
Malignant ependymoma in a dog. ( 14497569 )
1962
15
Malignant Ependymoma Masquerading as Tuberculous Meningitis: Clinico-Pathological Conference. ( 28907958 )
1962
16
Malignant ependymoma infiltrating the scalp. ( 14810337 )
1951

Variations for Malignant Ependymoma

Expression for Malignant Ependymoma

Search GEO for disease gene expression data for Malignant Ependymoma.

Pathways for Malignant Ependymoma

Pathways related to Malignant Ependymoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.09 NF2 YAP1

GO Terms for Malignant Ependymoma

Biological processes related to Malignant Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of neurogenesis GO:0050767 9.26 NF2 YAP1
2 negative regulation of extrinsic apoptotic signaling pathway GO:2001237 9.16 RELA YAP1
3 response to progesterone GO:0032570 8.96 RELA YAP1
4 regulation of stem cell proliferation GO:0072091 8.62 NF2 YAP1

Molecular functions related to Malignant Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 activating transcription factor binding GO:0033613 8.96 RELA YAP1
2 protein N-terminus binding GO:0047485 8.8 EPB41 ERCC5 RELA

Sources for Malignant Ependymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....